Tag Archives: NASDAQ:ATRS

A Director at Antares Pharma is Exercising Options

Today, a Director at Antares Pharma, Leonard Jacob, exercised options of Antares Pharma for $27.55K. The options were close to expired and Leonard Jacob retained stocks. Following this transaction Leonard Jacob’s holding in the company was increased by 15.62% to

Analysts Offer Insights on Healthcare Companies: Antares Pharma (NASDAQ: ATRS) and Galmed Pharmaceuticals (NASDAQ: GLMD)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (NASDAQ: ATRS) and Galmed Pharmaceuticals (NASDAQ: GLMD) with bullish sentiments. Antares Pharma (NASDAQ: ATRS) In a report released today, Oren

H.C. Wainwright Believes Antares Pharma (NASDAQ: ATRS) Still Has Room to Grow

In a report released today, Oren Livnat from H.C. Wainwright assigned a Buy rating to Antares Pharma (NASDAQ: ATRS), with a price target of $5. The company’s shares closed yesterday at $3.73, close to its 52-week high of $4.09. According

Antares Pharma Receives a New Rating from H.C. Wainwright

Antares Pharma (NASDAQ: ATRS) received a Buy rating and a $5 price target from H.C. Wainwright analyst Oren Livnat on September 8. The company’s shares closed on Friday at $3.04, close to its 52-week high of $3.37. According to TipRanks.com,

Analysts Offer Insights on Healthcare Companies: Antares Pharma (NASDAQ: ATRS) and Alnylam Pharma (NASDAQ: ALNY)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Antares Pharma (NASDAQ: ATRS) and Alnylam Pharma (NASDAQ: ALNY) with bullish sentiments. Antares Pharma (NASDAQ: ATRS) In a report issued on September

Piper Jaffray Believes Antares Pharma (NASDAQ: ATRS) Still Has Room to Grow

Piper Jaffray analyst David Amsellem reiterated a Buy rating on Antares Pharma (NASDAQ: ATRS) yesterday and set a price target of $4. The company’s shares closed yesterday at $3.18, close to its 52-week high of $3.37. According to TipRanks.com, Amsellem